AzurRx BioPharma, a company specializing in developing targeted, agreed to acquire First Wave Bio, a clinical-stage biotechnology company, for $229m. “The acquisition of First Wave Bio and the creation of First Wave BioPharma is a transformative event that significantly expands our GI development pipeline and positions our company for new growth opportunities in the inflammatory bowel disease [IBD] therapeutic space. We believe that our proprietary formulations of niclosamide, with their novel anti-inflammatory mechanism of action, non-systemic absorption, and safety benefits, will enable us to address significant unmet clinical needs for IBD patients, especially in the mild-to-moderate disease categories,” James Sapirstein, AzurRx BioPharma Chairman, President and CEO.